EGFR and colorectal cancer: However, several retrospective randomized studies provided evidence indicating that administering mAbs-targeting EGFR, such as cetuximab, does not provide any benefits to patients with advanced colorectal cancer with tumors containing activating mutations in the KRAS and other RAS family genes [231,232].